SEC Comment Letter 0000000000-24-006991 to Azitra, Inc. (AZTR)

Azitra, Inc.
Date: June 18, 2024 · CIK: 0001701478 · Accession: 0000000000-24-006991

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 18, 2024

Author

Francisco D. Salva

Form

UPLOAD

Company

Azitra, Inc.

Letter

United States securities and exchange commission logo June 18, 2024 Francisco D. Salva Chief Executive Officer Azitra, Inc. 21 Business Park Drive Branford, CT 06405 Re:Azitra, Inc. Draft Registration Statement on Form S-1 Submitted June 14, 2024 CIK No. 0001701478 Dear Francisco D. Salva: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue, Esq.

Show Raw Text

United States securities and exchange commission logo
June 18, 2024
Francisco D. Salva
Chief Executive Officer
Azitra, Inc.
21 Business Park Drive
Branford, CT 06405
Re:Azitra, Inc.
Draft Registration Statement on Form S-1
Submitted June 14, 2024
CIK No. 0001701478
Dear Francisco D. Salva:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Daniel K. Donahue, Esq.

SecProbe.io